statistiche ricercatore

GROSSI, FRANCESCO

Distribuzione geografica

Continente	#
EU - Europa	4.453
NA - Nord America	2.674
AS - Asia	295
Continente sconosciuto - Info sul continente non disponibili	4
OC - Oceania	2
SA - Sud America	2
Totale	7.430

Salva come PNG Salva come JPEG

Nazione	#
IT - Italia	3.267
US - Stati Uniti d'America	2.667
IE - Irlanda	569
SE - Svezia	191
SG - Singapore	178
GB - Regno Unito	162
RU - Federazione Russa	160
CN - Cina	60
DE - Germania	51
IN - India	23
FI - Finlandia	20
UA - Ucraina	15
TR - Turchia	10
BE - Belgio	9
JP - Giappone	9
HK - Hong Kong	7
CA - Canada	6
VN - Vietnam	6
EU - Europa	4
FR - Francia	3
AT - Austria	2
AU - Australia	2
TH - Thailandia	2
BG - Bulgaria	1
BR - Brasile	1
CH - Svizzera	1
LT - Lituania	1
MX - Messico	1
NL - Olanda	1
PE - Perù	1
Totale	7.430

Salva come PNG Salva come JPEG

Città	#
Milan	2.451
Dublin	569
Princeton	435
Fairfield	300
Boardman	260
Rome	218
Wilmington	195
Ashburn	194
Singapore	175
Nyköping	160
Chandler	131
San Diego	115
Woodbridge	110
Seattle	93
Ogden	86
Houston	81
Cambridge	74
London	65
Ann Arbor	56
Como	44
Santa Clara	39
Chicago	34
Pune	22
Dallas	21
Norwalk	21
Chiswick	18
Kilburn	16
Redmond	13
Washington	13
Helsinki	12
Jacksonville	12
Brussels	8
Prescot	8
Tokyo	8
Acton	7
New Bedfont	7
Assago	6
Frankfurt am Main	6
Hounslow	6
Kowloon	6
Munich	6
Southwark	6
Berlin	5
Guangzhou	5
Islington	5
Los Angeles	5
Wandsworth	5
Lappeenranta	4
Toronto	4
Turin	4
Varese	4
Boulder	3
Changsha	3
Dearborn	3
Dong Ket	3
Mountain View	3
Rutherford	3
Shanghai	3
Zhengzhou	3
Bangkok	2
Cassano d'Adda	2
Fayetteville	2
Jinan	2
Magnago	2
Modena	2
Moretta	2
Naples	2
Ottawa	2
Vienna	2
Wuhan	2
Aachen	1
Amsterdam	1
Beijing	1
Brescia	1
Bursa	1
Böblingen	1
Ceto	1
Changchun	1
Chengdu	1
Dalian	1
Dalmine	1
Deiva Marina	1
Denver	1
Esslingen am Neckar	1
Forest City	1
Fuyang	1
Fuzhou	1
Gatchina	1
Genoa	1
Gorizia	1
Hangzhou	1
Hefei	1
Huzhou	1
Izmir	1
Kocaeli	1
Lavis	1
Lima region	1
Long Beach	1
Melbourne	1
Miami Beach	1
Totale	6.224

Salva come PNG Salva come JPEG

Nome	#
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin	148
Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines.	96
Afatinib for the treatment of non-small cell lung cancer	68
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy	67
DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer	63
Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis	58
Novel treatment strategies for early-stage lung cancer: The oncologist’s perspective	52
Introduction of the beta isozyme of protein kinase C accelerates induced differentiation of murine erythroleukemia cells	51
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study	51
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)	50
Vinflunine for the treatment of non-small cell lung cancer	50
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation	49
Afatinib for the treatment of advanced non-small-cell lung cancer	48
Advances in treatment of mesothelioma	48
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy	48
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab	47
Exosomes: a new horizon in lung cancer	47
Update on the treatment of small cell lung cancer (SCLC)	47
Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects	46
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer	46
Liquid biopsy in non-small cell lung cancer: highlights and challenges	46
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds	46
A review of clinical practice guidelines and treatment recommendations for cancer care in the COVID-19 pandemic	46
Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis	45
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis	44
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study	44
Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: can we use enemy territory at our advantage?	44
Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice?	44
Hematopoietic growth factors in lung cancer	44
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib	44
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial	44
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy	44
COVID-19 vaccination in patients with classic Kaposi’s sarcoma	44
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial	43
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study	43
Oral Vinorelbine Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-Line Treatment for Patients with Advanced non- Squamous non- Small Cell Lung Cancer: a Cost Minimization Analysis in Twelve European Countries	43
Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers	43
New perspectives for the pharmacological and biological therapy of small cell lung cancer	43
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer	43
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer	43
Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer	42
Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study	41
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A randomized study	41
Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines	41
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors	41
Induction chemotherapy followed by concurrent standard radiotherapy and daily low dose cisplatin in locally advanced non-small-cell lung cancer	41
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy	41
Management of malignant pleural effusions	41
Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers	40
Looking for results in non-small-cell lung cancer: is bio-chemotherapy the right answer?	40
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine	40
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer.	40
Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases	39
Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy	39
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer	39
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial	39
Pleural and peripheral lung lesions: comparison of US- and CT-guided biopsy	39
Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer	39
Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib	39
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients	38
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells	38
Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers	38
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)	38
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.	38
Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine	38
IDH signalling pathway in cholangiocarcinoma: From biological rationale to therapeutic targeting	38
NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer	37
Successful treatment of lung adenocarcinoma with gefitinib based on EGFR gene amplification	37
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial	37
Managing patients with lung cancer - Common international guidelines must be developed	37
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes	37
Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001)	37
IL-12 Can Target Human Lung Adenocarcinoma Cells and Normal Bronchial Epithelial Cells Surrounding Tumor Lesions	37
Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview	37
Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer	37
Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: A phase II trial from an Italian cooperative group	37
Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study	37
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer	37
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy	37
Baseline characteristics and outcomes of cancer patients infected with sars-cov-2 in the lombardy region, italy (Aiom-l corona): A multicenter, observational, ambispective, cohort study	37
Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?	36
Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach	36
Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer	36
Ramucirumab: preclinical research and clinical development	36
CD133-Positive Cells from Non-Small Cell Lung Cancer Show Distinct Sensitivity to Cisplatin and Afatinib	36
Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries	36
Maintenance chemotherapy in non-small cell lung cancer	36
Systemic drug therapy of malignant pleural mesothelioma.	36
Role of microRNAs in malignant mesothelioma	36
Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases	36
Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity	36
Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective	36
Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: A review of the literature	36
A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019)	36
Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?	36
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial	36
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study	36
Use of nivolumab in elderly patients with advanced squamous non–small-cell lung cancer: results from the Italian cohort of an expanded access programme	36
Surgical resection of superior pulmonary sulcus tumor after neoadjuvant chemoradiation via the anterior transmanubrial approach: a case report	36
Trastuzumab deruxtecan: Changing the destiny of her2 expressing solid tumors	36
Totale	4.326

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	89.856
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	89.856

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2019/2020	33	0	0	0	0	0	5	7	7	6	4	0	4
2020/2021	41	0	5	0	5	0	10	0	4	4	3	2	8
2021/2022	1.833	0	5	1	0	430	190	192	151	232	186	105	341
2022/2023	1.155	225	49	70	40	78	310	4	69	84	176	16	34
2023/2024	3.882	483	689	646	787	905	116	26	52	146	12	3	17
2024/2025	914	17	29	581	41	35	211	0	0	0	0	0	0
Totale													7.956